Sarepta Therapeutics (NASDAQ:SRPT) Now Covered by HC Wainwright

HC Wainwright began coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note issued to investors on Monday, Marketbeat Ratings reports. The firm issued a sell rating and a $80.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for Sarepta Therapeutics’ Q4 2024 earnings at $1.53 EPS, FY2024 earnings at $2.30 EPS, Q1 2025 earnings at $2.32 EPS, Q2 2025 earnings at $2.69 EPS, Q3 2025 earnings at $2.75 EPS, Q4 2025 earnings at $2.82 EPS and FY2025 earnings at $10.58 EPS.

A number of other analysts have also recently issued reports on SRPT. StockNews.com cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Raymond James reissued an “outperform” rating and issued a $150.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Barclays cut their price objective on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Guggenheim boosted their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Finally, UBS Group raised their price target on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. One analyst has rated the stock with a sell rating, two have given a hold rating, twenty have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $175.77.

Sarepta Therapeutics Stock Up 5.7 %

Sarepta Therapeutics stock opened at $137.94 on Monday. Sarepta Therapeutics has a twelve month low of $78.67 and a twelve month high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The firm has a market cap of $13.18 billion, a PE ratio of 104.40 and a beta of 0.81. The firm’s 50 day moving average price is $121.90 and its two-hundred day moving average price is $131.39.

Insider Activity at Sarepta Therapeutics

In related news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the transaction, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. The trade was a 14.99 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 7.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in SRPT. Farallon Capital Management LLC raised its holdings in Sarepta Therapeutics by 102.8% during the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after purchasing an additional 1,243,427 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Sarepta Therapeutics by 32.3% during the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock worth $340,527,000 after buying an additional 665,087 shares during the last quarter. Erste Asset Management GmbH acquired a new position in Sarepta Therapeutics in the third quarter valued at approximately $79,425,000. Janus Henderson Group PLC boosted its stake in Sarepta Therapeutics by 14.2% in the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after acquiring an additional 543,143 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in Sarepta Therapeutics by 693.7% in the second quarter. Principal Financial Group Inc. now owns 363,011 shares of the biotechnology company’s stock valued at $57,356,000 after acquiring an additional 317,277 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.